V Agrapart
Overview
Explore the profile of V Agrapart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
157
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tredan O, Wang Q, Pissaloux D, Cassier P, de la Fouchardiere A, Fayette J, et al.
Ann Oncol
. 2019 Mar;
30(5):757-765.
PMID: 30865223
Background: Antitumor activity of molecular-targeted agents is guided by the presence of documented genomic alteration in specific histological subtypes. We aim to explore the feasibility, efficacy and therapeutic impact of...
2.
Campone M, Bachelot T, Penault-Llorca F, Pallis A, Agrapart V, Pierrat M, et al.
Cancer Chemother Pharmacol
. 2019 Jan;
83(4):743-753.
PMID: 30684019
Purpose: The primary objective of this multicentric dose allocation and dose expansion study was to determine the MTD and the DLTs of the lucitanib (a tyrosine kinase inhibitor of the...
3.
Bernichon E, Vallard A, Wang Q, Attignon V, Pissaloux D, Bachelot T, et al.
Ann Oncol
. 2017 Sep;
28(11):2773-2779.
PMID: 28945826
Background: Breast cancer (BC) patients with comparable prognostic features have heterogeneous outcomes, party related to a possible radiotherapy resistance leading to local-regional recurrences (LRR). The objective of the present study...
4.
Awada A, Dirix L, Manso Sanchez L, Xu B, Luu T, Dieras V, et al.
Ann Oncol
. 2012 Sep;
24(1):109-16.
PMID: 22967996
Background: Neratinib (HKI-272) is a potent irreversible pan-ErbB tyrosine kinase inhibitor with clinical activity in patients with ErbB2/HER2-positive breast cancer. Patients And Methods: Phase I of this open-label, phase I/II...